Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies

Vaccine

Volumn 18, Issue 18, 2000, Pages 1873-1885

  Pawlowski, Andrzej ^a   Källenius, Gunilla ^a,b   Svenson, Stefan B ^a,c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RABBIT;

ACETYLATION; ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIOLOGICAL TECHNIQUES; FEMALE; HAPTENS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INJECTIONS, INTRALYMPHATIC; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RABBITS; SULFHYDRYL COMPOUNDS; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0343067085     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00336-9     Document Type: Article

References (70)

1. World Health Organization. The world health report 1995: bridging the gaps. Geneva: WHO, vol. 9, 1995.
2. World Health Organization. Vaccine research and development: report of the technical review group meeting, 9-10 June, 1997.
3. Bruyn G.A.W., van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;897-910.
4. Moxon E.R., Kroll J.S. The role of bacterial polysaccharide capsules as virulence factors. Curr. Top. Microbiol. Immunol. 150:1990;65-85.
5. Guckian J.C., Christensen G.D., Fine D.P. The role of opsonins in recovery from experimental pneumococcal pneumonia. J. Infect. Dis. 142:1980;175-190.
6. Klemperer G., Klemperer F. Versuche über immunisirung und heilung bei der pneumokokkeninfection. Berlin Klin. Wochnschr. 28:1891;833-835.
7. Cole R. Treatment of pneumonia by means of specific serums. JAMA. 61:1913;663-666.
8. Tilghman R.C., Finland M. Clinical significance of bacteremia in pneumococcal pneumonia. Arch. Intern. Med. 59:1937;602-619.
9. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33:1995;2759-2762.
10. Austrian R., Boettger C., Dole M., Fairly L., Freid M. Streptococcus pneumoniae type 16A, a hitherto undescribed pneumococcal type. J. Clin. Microbiol. 22:1985;127-128.
11. Kenne L., Lindberg B. Bacterial polysaccharides. Aspinall G.O. The polysaccharides. vol. 2:1983;287-363 Academic Press, New York.
12. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60:1964;759-776.
13. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J. Infect. Dis. 136:(supp):1977;S38-S42.
14. Hilleman M.R., McClean A.A., Vella P.P., Weibel R.E., Woodhour A.F. Polyvalent pneumococcal polysaccharide vaccines. Bull. WHO. 56:1978;371-375.
15. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., Mäkalä P.H., Broome C.V., Facklam R.R., Tiesjema R.H., Parke J.C. Jr. Considerations for formulating the second generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1983;1136-1159.
16. Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax. 53:1998;159-162.
17. Hedlund J., Svenson S.B., Kalin M., Henrichsen J., Olsson-Liljequist B., Möllerberg G., Källenius G. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clin. Inf. Dis. 21:1995;948-953.
18. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Inf. Dis. 3:(supp):1981;S1-S17.
19. Ortqist A., Hedlund J., Burman L.A., Elbel E., Hofer M., Leinonen M., Lindblad I., Sundelof B., Kalin M. Randomised trial of 23-valent pneumococcal polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 351:1998;399-403.
20. Beuvery E.C., van Rossum F., Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37:1982;15-22.
21. Douglas R.M., Paton J.C., Duncan S.J., Hansman D.J. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148:1983;131-137.
22. Avery O.T., Goebel W.F. Chemo-immunological studies on conjugated carbohydrate proteins. V. Immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54:1931;437-447.
23. Svenson S.B., Lindberg A.A. Oligosaccharide-protein conjugate: a novel approach for making Salmonella O-antigen immunogens. FEMS Microbiol. Let. 1:1977;145-148.
24. Svenson S.B., Lindberg A.A. Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup BO-antigen and characterization of the antibody response. J. Immunol. 120:1978;1750-1757.
25. Svenson S.B., Lindberg A.A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J. Immunol. Methods. 25:1979;323-335.
26. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:1980;361-376.
27. Svenson S.B., Nurminen M., Lindberg A.A. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect. Immun. 25:1979;863-872.
28. Snippe H., Van Houte A.J., Van Dam J.E.G., De Reuver M.J., Jansze M.J., Willers J.M.N. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect. Immun. 40:1983;856-861.
29. De Velasco E.A., Verheul A.F.M., Veeneman G.H., Gomes L.J.F., van Boom J.H., Verhoef J., Snippe H. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine. 11:1993;1429-1436.
30. Lee C.J., Lock R.A., Andrew P.W., Mitchell T.J., Hansman D., Paton J.C. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide-pneumolysoid conjugate. Vaccine. 12:1994;875-878.
31. Saxena M., Di Fabio J.L. Salmonella typhi O-polysaccharide-tetanus toxoid conjugated vaccine. Vaccine. 12:1994;879-884.
32. Gu X.X., Sun J., Jin S., Barenkamp S.J., Lim D.J., Robbins J.B., Battey J. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect. Immun. 65:1997;4488-4493.
33. Lövik M., Aaberge I.S., Hoogerhout P., Poolman J., Pawlowski A., Svenson S.B. New type 6B conjugates: antibody response, protection, and different dependency on adjuvant and booster dose. First International Symposium on Pneumococci and Pneumococcal Diseases, Helsingör, Denmark. 1998;75. Abstract No. P89.
34. Aaberge I.S., Lövik M., Leikvold R., Groeng E.-C., Pawlowski A., Svenson S.B. Vaccination with type 6B polysaccharide-protein conjugates protects against challenge with type 6A pneumococci. First International Symposium on Pneumococci and Pneumococcal Diseases, Helsingör, Denmark. 1998;75. Abstract No. P88.
35. Wenger J.D., Heath P.T., Moxon R., Booy R. Epidemiological impact of conjugate vaccines against invasive disease caused by Haemophilus influenzae type b. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 2nd ed. 1997;489-502 Marcel Dekker, New York.
36. Kayhty H., Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2:1996;289-298.
37. Shann F. Pneumococcal vaccine: time for another controlled trial. Lancet. 351:1998;1600-1601.
38. Pawlowski A., Svenson S.B. A new simple method for producing antigenic fragments of bacterial polysaccharides for the preparation of conjugate vaccines. FEMS Microbiol. Lett. 174:1999;255-263.
39. Pawlowski A., Källenius G., Svenson S.B. A new method of non cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines. Vaccine. 17:1999;1474-1483.
40. Pawlowski A, Svenson SB. A new general method for producing non-crosslinked pneumococcal capsular polysaccharide-protein conjugate vaccines. In: First International Symposium on Pneumococci and Pneumococcal Diseases, Helsingör, Denmark, 1998. vol. 30. p. 61. Abstract No. 4-15.
41. Towbin H., Staehlin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Nat. Acad. Sci. USA. 76:1979;4350-4354.
42. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:1956;350-356.
43. Habeeb A.F.S.A. Determination of free amino groups in proteins by trinitrobenzene-sulfonic acid. Anal. Biochem. 14:1966;328-336.
44. Ellman G.L. Tissue sulfhydryl groups. Archives Biochem. Biophys. 82:1959;70-77.
45. Porro M., Viti P.C.S., Vannozzi F., Naggi A., Torri G. Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen. Molec. Immunol. 22:1985;907-919.
46. Fattom A., Vann W.F., Szu S.C., Sutton A., Li X., Bryla D., Schiffman G., Robbins J.B., Schneerson R. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect. Immun. 56:1988;2292-2298.
47. Peeters C.C., Tenbergen-Meekes A.M., Evenberg D.E., Poolman J., Zegers B.J.M., Rijkers G.T. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J. Immunol. 146:1991;4308-4314.
48. Vella P.P., Marburg S., Staub J.M., Kniskern P.J., Miller W., Hagopian A., Ip C., Tolman R.L., Rusk C.M., Chupac L.S., Ellis R.W. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F and 23F and a meningococcal outer membrane protein complex. Infect. Immun. 60:1992;4977-4983.
49. Lu C.H., Lee C.J., Kind P. Immune response of young mice to pneumococcal type 9 V polysaccharide-tetanus toxoid conjugate. Infect. Immun. 62:1994;2754-2760.
50. Laferrière C.A., Sood R.K., de Muys J.M., Michon F., Jennings H.J. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine. 15:1997;179-186.
51. Rodriguez M.E., van den Dobbelsteen G.P.J.M., Oomen L.A., de Weers O., van Buren L., Beurret M., Poolman J.T., Hoogerhout P. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine. 16:1998;1941-1949.
52. Seppälä I., Mäkelä O. Antigenicity of dextran-protein conjugates in mice: effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J. Immunol. 143:1989;1259-1264.
53. Anderson P.W., Pichichero M.E., Stein E.C., Porcell S., Betts R.F., Connuck D.M., Korones D., Insel R.A., Zahradnik J.M., Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM 197. J. Immunol. 142:1989;2464-2468.
54. Gray G.R. Antibodies to carbohydrates: preparation of antigens by coupling carbohydrates to proteins by reductive amination with cyanoborohydride. Methods in Enzymology. 50:1978;155-160.
55. Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., Johnson C., Madore D., Hogerman D. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J. 13:1994;368-372.
56. Askelöf P., Rodmalm K., Wrangsell G., Larsson U., Svenson S.B., Cowell J.L., Unden A., Bartfai T. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc. Natl. Acad. Sci. USA. 87:1990;1347-1351.
57. Peeters C.C.A.M., Tenbergen-Meekes A.M., Poolman J., Zegers B., Rijkers G. Immunogenicity of Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine. 10:1992;833-840.
58. Wessels M.R., Kasper D.L. Antibody recognition of the type 14 pneumococcal capsule: evidence for a conformational epitope in a neutral polysaccharide. J. Exp. Med. 169:1989;2121-2131.
59. Daum R.S., Hogerman D., Rennels M.B., Bewley K., Malinoski F., Rothstein E., Reisinger K., Block S., Keyserling H., Steinhoff M. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis. 176:1997;445-455.
60. Hausdorf W.P. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine. 14:1996;1179-1186.
61. Gray B.M., Converse G.M., Dillon H.C. Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage and infection during the first 24 months of life. J. Infect. Dis. 142:1980;923-933.
62. Klein J.O. The epidemiology of pneumococcal disease in infants and children. Rev. Infect. Dis. 3:1981;246-253.
63. Sniadack D.H., Schwartz B., Lipman H., Bogaerts J., Butler J.C., Dagan R., Echaniz-Aviles G., Lloyd-Evans N., Fenoll A., Girgis N.I., Henrichsen J., Klugman K., Lehmann D., Takala A.K., Vandepitte J., Gove S., Breiman R.F. Potential inverventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr. Infect. Dis. J. 14:1995;503-510.
64. Usen S., Adegbola R., Mulholland K., Jaffar S., Hilton S., Oparaugo A., Omosigho C., Lahai G., Corrah T., Palmer A., Schneider G., Weber M., Greenwood B. Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. Pediatr. Infect. Dis. J. 17:1998;23-28.
65. Dillard J.P., Vandersea M.W., Yother J. Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J. Exp. Med. 181:1995;973-983.
66. Garcia E., Arrecubieta C., Munoz R., Mollerach M., Lopez R. A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. Microb. Drug Resist. 3:1997;73-88.
67. Coffey T.J., Dowson C.G., Daniels M., Zhou J., Martin C., Spratt B.G., Musser J.M. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol. Biol. 5:1991;2255-2260.
68. Barnes D.M., Whittier S., Gilligan P.H., Soares S., Tomasz A., Henderson F.W. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J. Infect. Dis. 171:1995;890-896.
69. Hermans P.W., Sluijter M., Elzanaar K., van Veen A., Schonkeren J.J.M., Nooren F.M., van Leeuwen W.J., de Neeling A.J., van Klingeren B., Verbrugh H.A., de Groot R. Penicillin-resistant Streptococcus pneumoniae in the Netherlands: results of a 1-year molecular epidemiologic survey. J. Infect. Dis. 175:1997;1413-1422.
70. Gray B.M., Converse G.M., Dillon H.C. Jr. Serotypes of Streptococcus pneumoniae causing disease. J. Infect. Dis. 5:1979;201-207.